Stopping ACE-inhibitors in COVID-19

• Status: Completed
• Trial end date: 2021-02-24
• Target enrollment: 0
• Participant gender: All

Summary

ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University Innsbruck
• Collaborators: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK); Ludwig-Maximilians - University of Munich
• Treatments: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors

Criteria

Inclusion Criteria:

• Female and male patients competent to make a decision

• Proven and symptomatic SARS-CoV2 infection ≤ 5 days

• Patient age ≥ 18 years

• Provided written informed consent

• Chronic (≥ 1 month) ACEI/ARB therapy for treatment of arterial hypertension, diabetes mellitus, heart failure or coronary artery disease

• Stable hemodynamic conditions allowing to stop or continue treatment with ACEI/ARB (systolic blood pressure ≤180mmHg)

Exclusion Criteria:

• Women capable of bearing children as well as pregnant and breastfeeding women

• Participant in another interventional trail

• At screening visit, no oral medication intake possible

• Advanced heart failure NYHA Stage III-IV

• Left ventricular ejection fraction <30% or NTproBNP ≥600pg/mL in case of clinical signs of heart failure

• Acute coronary syndrome ≤ 3 months

• Severe arterial hypertension (concomitant use of more than 4 different antihypertensive drug classes)

• Acute respiratory distress syndrome with need for mechanical ventilation

• Patients who at not capable of home blood pressure monitoring

• Patients who cannot be switched to an alternative medication